Foley Trasimene Acquisition Corp. (WPF) Shareholders Approve Alight Solutions Deal
by Marlena Haddad on 2021-06-30 at 12:19pm

Foley Trasimene Acquisition Corp.  (NYSE:WPF) announced in a press release this morning that its shareholders approved its combination, as well as all other proposals, with workforce software firm Alight Solutions at a special meeting today.

Not all is settled, however, as Foley Trasimene extended the deadline for redemptions to 4 pm, July 1 in hopes that stockholders will have a change of mind.  As of the original redemption deadline June 28, stockholders elected to redeem 19,865,544 shares, reducing its trust from just over $1 billion to about $835 million. The extension will not allow any additional shareholders to redeem shares, but will allow redeemers to reverse course.

The SPAC’s sponsor also announced plans to buy up to 5.6 million shares that were previously submitted for redemption.  The transaction is expected to deliver approximately $2.68 billion of capital for Alight, which will be used for M&A purposes as well as other strategic investments, but the exact amount available at closing is still up in the air depending on the outcome from the new redemption deadline.

The transaction is expected to close on Friday July, 2 and the combined company’s stocks and warrants will trade on the New York Stock Exchange under the symbols “ALIT” and “ALIT.WS”, respectively, on Tuesday, July 6.

The parties initially announced the $7.3 billion deal on January 25. Alight software handles payroll and employee benefits with AI-backed personalized approaches and currently serves about 14% of the US working population.


ADVISORS

  • J.P. Morgan Securities LLC is acting as lead financial advisor and capital markets advisor to Alight.
  • Credit Suisse is acting as financial and capital markets advisor to Alight.
  • Barclays and Morgan Stanley & Co. LLC are also acting as financial and capital markets advisors to Alight.
  • BofA Securities is acting as financial advisor to Foley Trasimene.
  • Credit Suisse and J.P. Morgan Securities LLC acted as lead placement agents on the private offering.
  • BofA Securities also acted as placement agent.
  • Kirkland & Ellis LLP is acting as legal counsel to Alight.
  • Weil, Gotshal & Manges LLP is acting as legal counsel to Foley Trasimene.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved